Amplitude Inc vs GeneDx Holdings Corp — how do they compare? Amplitude Inc trades at $9.21 (market cap $1.22B), while GeneDx Holdings Corp trades at $65.4 (market cap $1.95B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and Amplitude Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| AMPL | WGS | |
|---|---|---|
Market Cap | $1.22B | $1.95B |
Sector | Technology | Technology |
52-Week High | $13.04 | $167.51 |
52-Week Low | $5.61 | $34.51 |
Enterprise Value | $1.05B | $1.95B |
Signals from Pluang's Aura AI — not financial advice
AMPL trades at $9.18, down 2.13% over the past day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, reaching $343.21M in 2025, yet the company remains unprofitable with a net income margin of -25.11%. Analyst consensus is bullish with a $9.25 price target, though recent news includes multiple law firm fraud investigations and a Bank of America downgrade citing profitability concerns.
The outlook hinges on AMPL's ability to translate robust revenue growth into profitability amid competitive pressures. Investment opportunity lies in potential margin expansion and market share gains, but risks include ongoing legal scrutiny, execution challenges, and persistent negative cash flows. The stock's near-term direction will likely be driven by upcoming earnings results and clarity on the fraud allegations.
GeneDx Holdings (WGS) trades at $65.64, down 5.4% over 24 hours, with a bullish technical signal from moving averages. The company reported revenue of $427.54 million in 2025 but a net loss of $21.02 million, with profitability metrics like ROE at -30.42% indicating financial strain. Recent news highlights a securities class action lawsuit filed against the company, alleging misleading statements related to the Fabric Genomics acquisition.
While analyst consensus remains strongly bullish with a $75.40 price target, the stock faces significant risks from ongoing litigation and persistent losses. Investment appeal hinges on the company's ability to improve margins and navigate legal challenges, but current fundamentals suggest caution despite optimistic Wall Street ratings.
Trailing returns across standard periods
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →